Radboudumc is the first hospital in the world to use a new genetic test on a large scale in clinical practice. This test ...

MyRisk TestSALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular ...

Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Genetic testing has had a shift in the past ten years, as it has left medical laboratories and entered living rooms.

Myriad Genetics has seen a subtle but notable uptick in its fair value estimate, with analysts revising the figure from $7.95 to $8.29. This slight increase comes as experts reassess the company's ...

Myriad Genetics (MYGN) stock is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue ...

Cellular Research Institute (CRI) Genetics is a company that provides ancestry, genetic, and DNA testing. It offers different test packages that may indicate a person’s history, health, or traits.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...

Bir Hospital has introduced a new diagnostic facility that can simultaneously test for 10 respiratory viruses, marking a ...

Get key insights from Myriad Genetics’ Q3 2025 earnings call, growth strategies, financial outlook, and new product launches.

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...